FACTORS AFFECTING USE OF MEDICATION TO TREAT ALCOHOLISM

影响使用药物治疗酗酒的因素

基本信息

批准号：
6371531
负责人：
TAMI L MARK
金额：
$ 12.88万
依托单位：
TRUVEN HEALTH ANALYTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
起止时间：
2000-07-01 至 2003-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6371531
关键词：
alcoholism /alcohol abuse chemotherapy behavioral /social science research tag clinical research decision making health care service evaluation health services research tag human subject naltrexone physicians

项目摘要

In January 1995, naltrexone, marketed under the name REVIATM became the first medication approved by the Food and Drug Administration for alcoholism treatment in almost 50 years. The ifficacy of naltrexone, as an adjunct to therapy, in decreasing the mean number of drinking days per week, the frequency of relapse, and subjective craving for alcohol with few side effects has been shown in double blind randomized clinical trials. Despite the evidence of its efficacy, reports of its use indicate that it is not as widespread as might be expected. Total prescription of Revia in 1998 (including prescription for narcotic treatment) were 13,000 per month, only slightly more than the number of prescriptions in 1996. The 1992 National Longitudinal Alcohol Epidemiologic Survey estimated that 13.7 million adults met the criteria for alcohol abuse and alcohol dependence during the year preceding the interview (Grant, 1995). The one-day census of specialty substance abuse providers (NDATUS) indicates that in 1996, there were 677,000 clients in treatment for alcoholism. This figure excludes persons receiving treatment for alcoholism in institutions specializing in mental health care and in primary care settings. Thus, perhaps only 2 percent of persons receiving alcoholism treatment are being treated with naltrexone. Given the low utilization of naltrexone in the face of its apparent efficacy, it is critical to understand the barriers to the adoption of this important new pharmacological tool. The goal of this proposed research is to identify the factors that are influencing the use of naltrexone and to gain insight into its perceived efficacy among practitioners. Towards this end, the primarily aims of this study are: (1) to identify factors influencing use of naltrexone and their relative importance; (2) to determine whether other new medications to treat alcoholism are likely to face barriers to prescribing; (3) to identify methods that physicians used to overcome barriers to prescribing naltrexone; (4) to collect information on the types of patients being prescribed naltrexone and the circumstances under which it is being prescribed. We propose to collect this information through experts panels and a national survey of physicians specialized in treating substance abuse.

1995 年 1 月，以 REVIATM 名称上市的纳曲酮成为近 50 年来美国食品和药物管理局批准的第一种用于治疗酒精中毒的药物。双盲随机临床试验显示了纳曲酮作为治疗辅助药物的功效，可以减少每周平均饮酒天数、复发频率和对酒精的主观渴望，且副作用很少。尽管有证据表明其功效，但其使用报告表明它并不像预期的那样广泛。 1998年Revia的处方总数（包括麻醉治疗处方）为每月13,000张，仅略高于1996年的处方数量。1992年全国纵向酒精流行病学调查估计，有1370万成年人符合酗酒和酒精依赖的标准采访前一年（Grant，1995）。专业药物滥用提供者一日普查 (NDATUS) 表明，1996 年，有 677,000 名客户正在接受酗酒治疗。这一数字不包括在专门从事精神卫生保健的机构和初级保健机构接受酗酒治疗的人。因此，也许只有 2% 的接受酗酒治疗的人正在接受纳曲酮治疗。鉴于纳曲酮虽然具有明显的功效，但其利用率较低，了解采用这种重要的新药理学工具的障碍至关重要。这项研究的目的是确定影响纳曲酮使用的因素，并深入了解从业者对纳曲酮的感知功效。为此，本研究的主要目的是：（1）确定影响纳曲酮使用的因素及其相对重要性； (2) 确定其他治疗酗酒的新药是否可能面临处方障碍； (3) 确定医生用来克服纳曲酮处方障碍的方法； (4) 收集有关服用纳曲酮的患者类型以及服用纳曲酮的情况的信息。我们建议通过专家小组和对专门治疗药物滥用的医生进行的全国调查来收集这些信息。